Not applicableEnded earlyNCT03786107
What this trial is testing
HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
Who this might be right for
Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerMetastatic Cervical Cancer
Puma Biotechnology, Inc. 1,583